$5.51
0.18% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US74365U1079
Symbol
TARA
Sector
Industry

Protara Therapeutics Inc Stock price

$5.51
+2.47 81.25% 1M
+3.34 153.92% 6M
+3.63 193.85% YTD
+3.63 193.09% 1Y
-0.98 15.10% 3Y
-8.89 61.74% 5Y
-397.29 98.63% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.01 0.18%
ISIN
US74365U1079
Symbol
TARA
Sector
Industry

Key metrics

Market capitalization $189.10m
Enterprise Value $112.34m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.39
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-45.88m
Free Cash Flow (TTM) Free Cash Flow $-35.26m
Cash position $81.50m
EPS (TTM) EPS $-2.82
P/E forward negative
Short interest 17.65%
Show more

Is Protara Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Protara Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Protara Therapeutics Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Protara Therapeutics Inc forecast:

Buy
100%

Financial data from Protara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.36 0.36
47% 47%
-
-0.36 -0.36
47% 47%
-
- Selling and Administrative Expenses 17 17
6% 6%
-
- Research and Development Expense 28 28
22% 22%
-
-46 -46
9% 9%
-
- Depreciation and Amortization 0.36 0.36
47% 47%
-
EBIT (Operating Income) EBIT -46 -46
8% 8%
-
Net Profit -42 -42
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Protara Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protara Therapeutics Inc Stock News

Positive
Seeking Alpha
15 days ago
Protara Therapeutics' TARA-002 showed promising Phase 2 results, significantly improving its valuation and offering a strong risk-reward setup despite recent stock fluctuations. The company raised $100M at $6.25 per share, ensuring a solid cash runway for potential Phase 3 trials and further development. Protara's current enterprise value is $70.2M, significantly undervalued compared to competi...
Neutral
GlobeNewsWire
17 days ago
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underwritten public offering of 13,690,000 shares of its common stock at a public offering price of $6.25 per share and pre-funded warrants to purchase 2,325,372 share...
Positive
Seeking Alpha
18 days ago
Protara Therapeutics' TARA-002 shows promising early data in bladder cancer, with a 72% complete response rate at 6 months in a small phase 2 trial. Financially, TARA has 7-8 quarters of funds, potentially extending to 3-4 years with a $100 million capital raise. Despite positive early data, the small patient sample size necessitates caution; larger trials are needed to confirm efficacy and saf...
More Protara Therapeutics Inc News

Company Profile

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.

Head office United States
CEO Jesse Shefferman
Employees 27
Founded 2006
Website www.protaratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today